Transcatheter renal denervation in patients with resistant hypertension and type 2 diabetes mellitus has beneficial effects beyond blood pressure reduction

А.Ю. Фальковская, В.Ф. Мордовин, С.Е. Пекарский, А.Е. Баев, Г.В. Семке, Т.М. Рипп, В.А. Личикаки, А.Л. Крылов

Authors: A.Yu. Falkovskaya, v.F. Mordovin, S.E. Pekarskiy, A.E. Baev, G.V. Semke, T.M. Ripp, V.A. Lichikaki, A.L. Krylov

Place: Tomsk, Russia

Institution: Research Institute of Cardiology SB RAMS, Department of Clinical Cardiology

Abstract:

Objective. To evaluate blood pressure (BP) lowering and dynamics of fasting glucose after transcatheter renal denervation (TRD) in patients with true resistant hypertension and type 2 diabetes mellitus (T2DM). Design and methods. Twenty five patients with essential hypertension and T2DM with systolic BP (SBP) > 150 mmHg were included. Office BP measurement, 24-h ambulatory BP monitoring, renal Doppler ultrasound and assessment of fasting glucose and renal function (creatinine, estimated glomerular filtration rate) were performed at baseline and 6 months after TRD. None of the patients changed the antidiabetic and antihypertensive treatment during follow-up. Fourteen patients completed 6-month follow-up. Results. TRD led to a significant reduction in systolic and diastolic 24-h BP (-22,7/-9,2 mmHg, p = 0,01/0,02), as well as office BP (-10,4/5,2 mmHg, p = 0,0005/0,01) and did not affect negatively renal function. Ten patients (71 %) were responders with the office SBP reduction > 10 mmHg. TRD was associated with significant reduction in fasting glucose levels (-2,0 mmol/L, p

Keywords: resistant hypertension, diabetes mellitus, renal denervation

364.85 KB 6